Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | FURIN | P09958 | 10/20 | 0.34 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18661790 | 1.00 | SMN1; SMN2 (0.34) | SMN1; SMN2FURINC3AR1PRSS1REN | |
| SCHEMBL18661754 | 1.00 | SMN1; SMN2 (0.34) | SMN1; SMN2FURINC3AR1PRSS1REN | |
| SCHEMBL24571690 | 0.90 | FURIN (0.37) | SMN1; SMN2FURINC3AR1PRSS1REN | |
| SCHEMBL26499160 | 0.90 | SMN1; SMN2 (0.34) | SMN1; SMN2FURINC3AR1PRSS1REN | |
| SCHEMBL19678198 | 0.90 | FURIN (0.36) | SMN1; SMN2FURINC3AR1PRSS1REN | |
| SCHEMBL23220183 | 0.88 | FURIN (0.33) | SMN1; SMN2FURINC3AR1PRSS1REN | |
| SCHEMBL19198733 | 0.88 | FURIN (0.33) | SMN1; SMN2FURINC3AR1PRSS1REN | |
| SCHEMBL24136141 | 0.88 | FURIN (0.35) | FURINPRSS1REN | |
| SCHEMBL24420899 | 0.88 | FURIN (0.33) | SMN1; SMN2FURINC3AR1PRSS1REN | |
| SCHEMBL25448089 | 0.88 | FURIN (0.35) | SMN1; SMN2FURINC3AR1PRSS1REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198314-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | SUTRO BIOPHARMA, INC. | 2021-07-01 | — | — | US | disclosed |
| EP-3617221-A1 | CYTOTOXIN AND CONJUGATE, USES OF SAME, AND PREPARATION METHOD THEREFOR | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2020-03-04 | — | — | EP | disclosed |
| WO-2016008112-A1 | LINKERS AND APPLICATION TOWARDS ADC THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2016-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198314-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | CYP17A1, HSD17B7, SHBG | SMN1; SMN2 2005/4885FURIN 3399/4885C3AR1 2114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.